Cariad Chester
Director/Miembro de la Junta en Plexium, Inc. .
Cargos activos de Cariad Chester
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Inversor de Capital Privado | 01/01/2021 | - |
Plexium, Inc.
Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 23/02/2022 | - |
TCG Crossover Management LLC
TCG Crossover Management LLC Investment ManagersFinance TCG Crossover Management LLC (TCG Crossover Management) is a venture capital firm founded in 2021 by Chen-Ming Yu. The firm is headquartered in Palo Alto, California. | Inversor de Capital Privado | 01/01/2021 | - |
Historial de carrera de Cariad Chester
Antiguos cargos conocidos de Cariad Chester.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Director/Miembro de la Junta | 01/05/2023 | 29/11/2023 |
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo Capital Management LLC (Aquilo) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. Aquilo was founded in 2010 to manage investment funds and separately managed accounts for individual clients. | Analyst-Equity | 01/01/2015 | 31/12/2021 |
Corporate Officer/Principal | - | 31/12/2021 |
Formación de Cariad Chester.
Swarthmore College | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Director/Board Member | 3 |
Private Equity Investor | 2 |
Analyst-Equity | 1 |
Sectorial
Finance | 4 |
Consumer Services | 2 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo Capital Management LLC (Aquilo) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. Aquilo was founded in 2010 to manage investment funds and separately managed accounts for individual clients. | Finance |
Plexium, Inc.
Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Health Technology |
TCG Crossover Management LLC
TCG Crossover Management LLC Investment ManagersFinance TCG Crossover Management LLC (TCG Crossover Management) is a venture capital firm founded in 2021 by Chen-Ming Yu. The firm is headquartered in Palo Alto, California. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
- Bolsa de valores
- Insiders
- Cariad Chester
- Experiencia